|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 736.95 INR | -0.96% |
|
+0.03% | -1.94% |
| 11-13 | Supriya Lifescience Limited, Q2 2026 Earnings Call, Nov 13, 2025 | |
| 11-12 | Supriya Lifescience Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 | CI |
| Capitalization | 59.31B 654M 564M 525M 488M 909M 978M 6.03B 2.38B 28.29B 2.45B 2.4B 103B | P/E ratio 2026 * |
30.3x | P/E ratio 2027 * | 23.9x |
|---|---|---|---|---|---|
| Enterprise value | 59.31B 654M 564M 525M 488M 909M 978M 6.03B 2.38B 28.29B 2.45B 2.4B 103B | EV / Sales 2026 * |
7.11x | EV / Sales 2027 * | 5.75x |
| Free-Float |
27.82% | Yield 2026 * |
-
| Yield 2027 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Supriya Lifescience Limited
| 1 day | -0.96% | ||
| 1 week | +0.03% | ||
| Current month | -1.94% | ||
| 1 month | +0.12% | ||
| 3 months | -0.22% | ||
| 6 months | +2.31% | ||
| Current year | -1.94% |
| 1 week | 720 |  | 750 |
| 1 month | 720 | | 775 |
| Current year | 720 | | 775 |
| 1 year | 556.15 | | 842 |
| 3 years | 170.15 | | 842 |
| 5 years | 170.15 | | 842 |
| 10 years | 170.15 | | 842 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 34 | 31/07/2024 | |
| Chief Executive Officer | 35 | 31/07/2024 | |
| Director of Finance/CFO | - | 22/01/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | 24/03/2021 | |
| Director/Board Member | 73 | 23/01/2025 | |
| Director/Board Member | 66 | 24/03/2021 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.96% | +0.03% | +6.30% | +229.07% | 654M | |
| +0.53% | -2.37% | +43.09% | +190.27% | 930B | |
| -0.41% | +6.98% | +48.72% | +26.86% | 527B | |
| -0.31% | -2.60% | +24.94% | +40.25% | 379B | |
| +0.93% | +2.38% | +31.46% | +18.47% | 371B | |
| +0.19% | -1.15% | +28.47% | +21.14% | 292B | |
| +0.98% | +1.37% | +29.42% | +35.03% | 276B | |
| -1.93% | -1.54% | +11.14% | -1.47% | 270B | |
| +6.49% | +1.95% | -32.44% | -18.44% | 268B | |
| +0.12% | +1.32% | +21.43% | +22.64% | 178B | |
| Average | +0.56% | +0.64% | +21.25% | +56.38% | 349.16B | |
| Weighted average by Cap. | +0.59% | +0.50% | +29.04% | +65.26% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.34B 91.93M 79.25M 73.78M 68.68M 128M 138M 849M 335M 3.98B 345M 338M 14.53B | 10.31B 114M 98M 91.23M 84.93M 158M 170M 1.05B 414M 4.92B 426M 418M 17.96B |
| Net income | 1.95B 21.54M 18.57M 17.28M 16.09M 29.96M 32.23M 199M 78.39M 932M 80.76M 79.1M 3.4B | 2.48B 27.28M 23.52M 21.89M 20.38M 37.95M 40.83M 252M 99.29M 1.18B 102M 100M 4.31B |
| Net Debt | - | - |
More financial data
* Estimated data
Employees
515
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/01/26 | 736.95 ₹ | -0.96% | 125,179 |
| 14/01/26 | 744.10 ₹ | +0.74% | 79,865 |
| 13/01/26 | 738.60 ₹ | -0.50% | 73,839 |
| 12/01/26 | 742.30 ₹ | +0.76% | 206,867 |
| 09/01/26 | 736.70 ₹ | -3.70% | 189,131 |
End-of-day quote NSE India S.E., January 15, 2026
More quotes
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SUPRIYA Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition